Vedolizumab

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2759 publications

Comparative Effectiveness of Vedolizumab and Ustekinumab in Biologic-Experienced Ulcerative Colitis: A Real-World Multicenter Study from the Güntürk Group.

Comparative Effectiveness of Vedolizumab and Ustekinumab in Biologic-Experienced Ulcerative Colitis: A Real-World Multicenter Study from the Güntürk Group.

Journal: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Published: October 23, 2026

Association between vedolizumab levels and clinical outcomes in pouchitis

Association between vedolizumab levels and clinical outcomes in pouchitis

Journal: Harefuah

Published: October 18, 2026

Editorial: Taking a Different Route-Navigating the Switch From Intravenous to Subcutaneous Vedolizumab. Authors' Reply.

Editorial: Taking a Different Route-Navigating the Switch From Intravenous to Subcutaneous Vedolizumab. Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 13, 2026

Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims Analysis.

Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims Analysis.

Journal: Internal medicine (Tokyo, Japan)

Published: October 07, 2026

Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort.

Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort.

Journal: Journal of the Canadian Association of Gastroenterology

Published: October 07, 2026

Editorial: Taking a Different Route-Navigating the Switch From Intravenous to Subcutaneous Vedolizumab.

Editorial: Taking a Different Route-Navigating the Switch From Intravenous to Subcutaneous Vedolizumab.

Journal: Alimentary pharmacology & therapeutics

Published: September 28, 2026

Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies.

Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies.

Journal: Journal of Crohn's & colitis

Published: September 25, 2026

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis.

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis.

Journal: JAMA network open

Published: September 25, 2026

Successful combination therapy with ustekinumab and intensive granulocyte and monocyte adsorptive apheresis in highly refractory pediatric ulcerative colitis: pathophysiological rationale and clinical outcome.

Successful combination therapy with ustekinumab and intensive granulocyte and monocyte adsorptive apheresis in highly refractory pediatric ulcerative colitis: pathophysiological rationale and clinical outcome.

Journal: Immunological medicine

Published: September 24, 2026

A Case of Refractory Pouchitis with Postoperative Anal Stenosis after Ileal Pouch-anal Anastomosis Treated with Vedolizumab, a Radial Incision and Cutting.

A Case of Refractory Pouchitis with Postoperative Anal Stenosis after Ileal Pouch-anal Anastomosis Treated with Vedolizumab, a Radial Incision and Cutting.

Journal: Internal medicine (Tokyo, Japan)

Published: September 23, 2026

Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.

Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.

Journal: Journal of Crohn's & colitis

Published: September 22, 2026

Prior Ustekinumab Exposure and Ulcerative Colitis Are Associated with Suboptimal Trough Levels in Patients Receiving Advanced-Line Vedolizumab or Ustekinumab for Inflammatory Bowel Disease: A Cross-Sectional Cohort Study.

Prior Ustekinumab Exposure and Ulcerative Colitis Are Associated with Suboptimal Trough Levels in Patients Receiving Advanced-Line Vedolizumab or Ustekinumab for Inflammatory Bowel Disease: A Cross-Sectional Cohort Study.

Journal: Biomedicines

Published: September 08, 2026

Showing 1-12 of 2,759

Last Updated: 11/08/2026